The GALNT6‑LGALS3BP axis promotes breast cancer cell growth

Kimura,Ryuichiro; Yoshimaru,Tetsuro; Matsushita,Yosuke; Matsuo,Taisuke; Ono,Masaya; Park,Jae‑Hyun; Sasa,Mitsunori; Miyoshi,Yasuo; Nakamura,Yusuke; Katagiri,Toyomasa

doi:10.3892/ijo.2019.4941

The GALNT6‑LGALS3BP axis promotes breast cancer cell growth

Authors:
- Ryuichiro Kimura
- Tetsuro Yoshimaru
- Yosuke Matsushita
- Taisuke Matsuo
- Masaya Ono
- Jae‑Hyun Park
- Mitsunori Sasa
- Yasuo Miyoshi
- Yusuke Nakamura
- Toyomasa Katagiri
View Affiliations

Affiliations: Division of Genome Medicine, Institute of Advanced Medical Sciences, Tokushima University, Tokushima, Tokushima 770‑8503, Japan, Division of Genome Medicine, Institute of Advanced Medical Sciences, Tokushima University, Tokushima, Tokushima 770‑8503, Japan, Division of Chemotherapy and Clinical Research, National Cancer Center Research Institute, Tokyo 104‑0045, Japan, Cancer Precision Medicine, Inc., Kawasaki, Kanagawa 210‑0821, Japan, Department of Surgery, Tokushima Breast Care Clinic, Tokushima, Tokushima 770‑0052, Japan, Department of Surgery, Division of Breast and Endocrine Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo 663‑8501, Japan, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo 135‑8550, Japan
Published online on: December 13, 2019 https://doi.org/10.3892/ijo.2019.4941
Pages: 581-595

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Polypeptide N‑acetylgalactosaminyltransferase 6 (GALNT6), which is involved in the initiation of O‑glycosylation, has been reported to play crucial roles in mammary carcinogenesis through binding to several substrates; however, its biological roles in mediating growth‑promoting effects remain unknown. The present study demonstrated a crucial pathophysiological role of GALNT6 through its O‑glycosylation of lectin galactoside‑binding soluble 3 binding protein (LGALS3BP), a secreted growth‑promoting glycoprotein, in breast cancer growth. The Cancer Genome Atlas data analysis revealed that high expression levels of GALNT6 were significantly associated with poor prognosis of breast cancer. GALNT6 O‑glycosylated LGALS3BP in breast cancer cells, whereas knockdown of GALNT6 by siRNA led to the inhibition of both the O‑glycosylation and secretion of LGALS3BP, resulting in the suppression of breast cancer cell growth. Notably, LGALS3BP is potentially O‑glycosylated at three sites (T556, T571 and S582) by GALNT6, thereby promoting autocrine cell growth, whereas the expression of LGALS3BP with three Ala substitutions (T556A, T571A and S582A) in cells drastically reduced GALNT6‑dependent LGALS3BP O‑glycosylation and secretion, resulting in suppression of autocrine growth‑promoting effect. The findings of the present study suggest that the GALNT6‑LGALS3BP axis is crucial for breast cancer cell proliferation and may be a therapeutic target and biomarker for mammary tumors.

View Figures

View References

1	Tarp MA and Clausen H: Mucin-type O-glycosylation and its potential use in drug and vaccine development. Biochim Biophys Acta. 1780:546–563. 2008. View Article : Google Scholar
2	Gill DJ, Clausen H and Bard F: Location, location, location: New insights into O-GalNAc protein glycosylation. Trends Cell Biol. 21:149–158. 2011. View Article : Google Scholar
3	Schjoldager KT and Clausen H: Site-specific protein O-glycosylation modulates proprotein processing-deciphering specific functions of the large polypeptide GalNAc-transferase gene family. Biochim Biophys Acta. 1820:2079–2094. 2012. View Article : Google Scholar : PubMed/NCBI
4	Pinho SS and Reis CA: Glycosylation in cancer: Mechanisms and clinical implications. Nat Rev Cancer. 15:540–555. 2015. View Article : Google Scholar : PubMed/NCBI
5	Hakomori S: Glycosylation defining cancer malignancy: New wine in an old bottle. Proc Natl Acad Sci USA. 99:10231–10233. 2002. View Article : Google Scholar : PubMed/NCBI
6	Hussain MR, Hoessli DC and Fang M: N-acetylgalact osaminyl-transferases in cancer. Oncotarget. 7:54067–54081. 2016. View Article : Google Scholar : PubMed/NCBI
7	Berois N, Mazal D, Ubillos L, Trajtenberg F, Nicolas A, Sastre-Garau X, Magdelenat H and Osinaga E: UDP-N-acetyl-D-galactosamine: Polypeptide N-acetylgalactosaminyltransferase-6 as a new immunohistochemical breast cancer marker. J Histochem Cytochem. 54:317–328. 2006. View Article : Google Scholar
8	Freire T, Berois N, Sóñora C, Varangot M, Barrios E and Osinaga E: UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6 (ppGalNAc-T6) mRNA as a potential new marker for detection of bone marrow-disseminated breast cancer cells. Int J Cancer. 119:1383–1388. 2006. View Article : Google Scholar : PubMed/NCBI
9	Patani N, Jiang W and Mokbel K: Prognostic utility of glycosyltransferase expression in breast cancer. Cancer Genomics Proteomics. 5:333–340. 2008.
10	Park JH, Nishidate T, Kijima K, Ohashi T, Takegawa K, Fujikane T, Hirata K, Nakamura Y and Katagiri T: Critical roles of mucin 1 glycosylation by transactivated polypeptide N-acetylg alactosaminyltransferase 6 in mammary carcinogenesis. Cancer Res. 70:2759–2769. 2010. View Article : Google Scholar : PubMed/NCBI
11	Liesche F, Kölbl AC, Ilmer M, Hutter S, Jeschke U and Andergassen U: Role of N-acetylgalactosaminyltransferase 6 in early tumorigenesis and formation of metastasis. Mol Med Rep. 13:4309–4314. 2016. View Article : Google Scholar : PubMed/NCBI
12	Lin TC, Chen ST, Huang MC, Huang J, Hsu CL, Juan HF, Lin HH and Chen CH: GALNT6 expression enhances aggressive phenotypes of ovarian cancer cells by regulating EGFR activity. Oncotarget. 8:42588–42601. 2017.PubMed/NCBI
13	Sheta R, Bachvarova M, Plante M, Gregoire J, Renaud MC, Sebastianelli A, Popa I and Bachvarov D: Altered expression of different GalNAc-transferases is associated with disease progression and poor prognosis in women with high-grade serous ovarian cancer. Int J Oncol. 51:1887–1897. 2017. View Article : Google Scholar : PubMed/NCBI
14	Kitada S, Yamada S, Kuma A, Ouchi S, Tasaki T, Nabeshima A, Noguchi H, Wang KY, Shimajiri S, Nakano R, et al: Polypeptide N-acetylgalactosaminyl transferase 3 independently predicts high-grade tumours and poor prognosis in patients with renal cell carcinomas. Br J Cancer. 109:472–481. 2013. View Article : Google Scholar : PubMed/NCBI
15	Li Z, Yamada S, Wu Y, Wang KY, Liu YP, Uramoto H, Kohno K and Sasaguri Y: Polypeptide N-acetylgalactosaminyltransferase-6 expression independently predicts poor overall survival in patients with lung adenocarcinoma after curative resection. Oncotarget. 7:54463–54473. 2016.PubMed/NCBI
16	Li Z, Yamada S, Inenaga S, Imamura T, Wu Y, Wang KY, Shimajiri S, Nakano R, Izumi H, Kohno K and Sasaguri Y: Polypeptide N-acetylgalactosaminyltransferase 6 expression in pancreatic cancer is an independent prognostic factor indicating better overall survival. Br J Cancer. 104:1882–1889. 2011. View Article : Google Scholar : PubMed/NCBI
17	Park JH, Katagiri T, Chung S, Kijima K and Nakamura Y: Polypeptide N-acetylgalactosaminyltransferase 6 disrupts mammary acinar morphogenesis through O-glycosylation of fibronectin. Neoplasia. 13:320–326. 2011. View Article : Google Scholar : PubMed/NCBI
18	Tarhan YE, Kato T, Jang M, Haga Y, Ueda K, Nakamura Y and Park JH: Morphological changes, cadherin switching, and growth suppression in pancreatic cancer by GALNT6 knockdown. Neoplasia. 18:265–272. 2016. View Article : Google Scholar : PubMed/NCBI
19	Lin J, Chung S, Ueda K, Matsuda K, Nakamura Y and Park JH: GALNT6 stabilizes GRP78 protein by O-glycosylation and enhances its activity to suppress apoptosis under stress condition. Neoplasia. 19:43–53. 2017. View Article : Google Scholar : PubMed/NCBI
20	Deng B, Tarhan YE, Ueda K, Ren L, Katagiri T, Park JH and Nakamura Y: Critical role of estrogen receptor alpha O-glycosylation by N-acetylgalactosaminyltransferase 6 (GALNT6) in its nuclear localization in breast cancer cells. Neoplasia. 20:1038–1044. 2018. View Article : Google Scholar : PubMed/NCBI
21	Koths K, Taylor E, Halenbeck R, Casipit C and Wang A: Cloning and characterization of a human Mac-2-binding protein, a new member of the superfamily defined by the macrophage scavenger receptor cysteine-rich domain. J Biol Chem. 268:14245–14249. 1993.PubMed/NCBI
22	Ullrich A, Sures I, D’Egidio M, Jallal B, Powell TJ, Herbst R, Dreps A, Azam M, Rubinstein M, Natoli C, et al: The secreted tumor-associated antigen 90K is a potent immune stimulator. J Biol Chem. 269:18401–18407. 1994.PubMed/NCBI
23	Iacobelli S, Arnò E, D’Orazio A and Coletti G: Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer. Cancer Res. 46:3005–3010. 1986.PubMed/NCBI
24	Linsley PS, Horn D, Marquardt H, Brown JP, Hellström I, Hellström KE, Ochs V and Tolentino E: Identification of a novel serum protein secreted by lung carcinoma cells. Biochemistry. 25:2978–2986. 1986. View Article : Google Scholar : PubMed/NCBI
25	Iacobelli S, Bucci I, D’Egidio M, Giuliani C, Natoli C, Tinari N, Rubistein M and Schlessinger J: Purification and characterization of a 90 kDa protein released from human tumors and tumor cell lines. FEBS Lett. 319:59–65. 1993. View Article : Google Scholar : PubMed/NCBI
26	Iacobelli S, Sismondi P, Giai M, D’Egidio M, Tinari N, Amatetti C, Di Stefano P and Natoli C: Prognostic value of a novel circulating serum 90K antigen in breast cancer. Br J Cancer. 69:172–176. 1994. View Article : Google Scholar : PubMed/NCBI
27	Tinari N, Lattanzio R, Querzoli P, Natoli C, Grassadonia A, Alberti S, Hubalek M, Reimer D, Nenci I, Bruzzi P, et al: High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies. Int J Cancer. 124:333–338. 2009. View Article : Google Scholar
28	Fornarini B, D’Ambrosio C, Natoli C, Tinari N, Silingardi V and Iacobelli S: Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. Blood. 96:3282–3285. 2000. View Article : Google Scholar : PubMed/NCBI
29	Strizzi L, Muraro R, Vianale G, Natoli C, Talone L, Catalano A, Mutti L, Tassi G and Procopio A: Expression of glycoprotein 90K in human malignant pleural mesothelioma: Correlation with patient survival. J Pathol. 197:218–223. 2002. View Article : Google Scholar : PubMed/NCBI
30	Marchetti A, Tinari N, Buttitta F, Chella A, Angeletti CA, Sacco R, Mucilli F, Ullrich A and Iacobelli S: Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. Cancer Res. 62:2535–2539. 2002.PubMed/NCBI
31	Grassadonia A, Tinari N, Iurisci I, Piccolo E, Cumashi A, Innominato P, D’Egidio M, Natoli C, Piantelli M and Iacobelli S: 90K (Mac-2 BP) and galectins in tumor progression and metastasis. Glycoconj J. 19:551–556. 2002. View Article : Google Scholar
32	Grassadonia A, Tinari N, Natoli C, Yahalom G and Iacobelli S: Circulating autoantibodies to LGALS3BP: A novel biomarker for cancer. Dis Markers. 35:747–752. 2013. View Article : Google Scholar : PubMed/NCBI
33	Fukawa T, Ono M, Matsuo T, Uehara H, Miki T, Nakamura Y, Kanayama HO and Katagiri T: DDX31 regulates the p53-HDM2 pathway and rRNA gene transcription through its interaction with NPM1 in renal cell carcinoma. Cancer Res. 72:5867–5877. 2012. View Article : Google Scholar : PubMed/NCBI
34	Hang HC, Yu C, Ten Hagen KG, Tian E, Winans KA, Tabak LA and Bertozzi CR: Small molecule inhibitors of mucin-type O-linked glycosylation from a uridine-based library. Chem Biol. 11:337–345. 2004. View Article : Google Scholar : PubMed/NCBI
35	Ono M, Shitashige M, Honda K, Isobe T, Kuwabara H, Matsuzuki H, Hirohashi S and Yamada T: Label-free quantitative proteomics using large peptide data sets generated by nanoflow liquid chromatography and mass spectrometry. Mol Cell Proteomics. 5:1338–1347. 2006. View Article : Google Scholar : PubMed/NCBI
36	Hohenester E, Sasaki T and Timpl R: Crystal structure of a scavenger receptor cysteine-rich domain sheds light on an ancient superfamily. Nat Struct Biol. 6:228–232. 1999. View Article : Google Scholar : PubMed/NCBI
37	Hellstern S, Sasaki T, Fauser C, Lustig A, Timpl R and Engel J: Functional studies on recombinant domains of Mac-2-binding protein. J Biol Chem. 277:15690–15696. 2002. View Article : Google Scholar : PubMed/NCBI
38	Sasaki T, Brakebusch C, Engel J and Timpl R: Mac-2 binding protein is a cell-adhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds beta1 integrins, collagens and fibronectin. EMBO J. 17:1606–1613. 1998. View Article : Google Scholar : PubMed/NCBI
39	Müller SA, Sasaki T, Bork P, Wolpensinger B, Schulthess T, Timpl R, Engel A and Engel J: Domain organization of Mac-2 binding protein and its oligomerization to linear and ring-like structures. J Mol Biol. 291:801–813. 1999. View Article : Google Scholar : PubMed/NCBI
40	Stampolidis P, Ullrich A and Iacobelli S: LGALS3BP, lectin galactoside-binding soluble 3 binding protein, promotes oncogenic cellular events impeded by antibody intervention. Oncogene. 34:39–52. 2015. View Article : Google Scholar
41	Fogeron ML, Müller H, Schade S, Dreher F, Lehmann V, Kühnel A, Scholz AK, Kashofer K, Zerck A, Fauler B, et al: LGALS3BP regulates centriole biogenesis and centrosome hypertrophy in cancer cells. Nat Commun. 4:15312013. View Article : Google Scholar : PubMed/NCBI
42	Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature. 490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
43	Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, et al: Comprehensive molecular portraits of invasive lobular breast cancer. Cell. 163:506–519. 2015. View Article : Google Scholar : PubMed/NCBI
44	Györffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q and Szallasi Z: An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 123:725–731. 2010. View Article : Google Scholar